Amgen’s Humira biosimilar delayed, Enbrel approved
Amgen’s Humira biosimilar Amjevita will be delayed at least through 2017 due to litigation by competitor AbbVie. The maker of Humira filed a patent infringement claim against Amgen on Aug. 4, alleging that the drug also violates the Biosimilar Price Competition and Innovation Act. Amgen was approved to market its biosimilar Sept. 23 by the Read More →
Read More →Resonant’s third quarter losses grow
Goleta-based Resonant reported a $4 million net loss, or a loss of 39 cents per diluted share, for the third quarter of 2016, up from a $2.9 million — or 40 cents per diluted share — loss in 2015. Revenues from contracts with four customers were $25,000 for the quarter ended Sept. 30. General and Read More →
Read More →Sientra loses $10 million in third quarter
Sientra reported a net loss of $10 million for the third quarter of 2016, ended Sept. 30, and announced the acquisition of a new line of products. Sales for the Goleta-based breast implant manufacturer fell from $9.9 million in the third quarter of 2015 to $6.5 million this quarter, while operating expenses rose 15.3 percent. Read More →
Read More →Sientra settles lawsuits over public offering
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Joens: A fond farewell to the tri-county technology scene
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →